País: Canadá
Língua: inglês
Origem: Health Canada
TERBINAFINE (TERBINAFINE HYDROCHLORIDE)
MYLAN PHARMACEUTICALS ULC
D01BA02
TERBINAFINE
250MG
TABLET
TERBINAFINE (TERBINAFINE HYDROCHLORIDE) 250MG
ORAL
100
Prescription
ALLYLAMINES
Active ingredient group (AIG) number: 0132855002; AHFS:
CANCELLED POST MARKET
2017-01-09
Page 1 of 43 PRODUCT MONOGRAPH Pr MYLAN-TERBINAFINE Terbinafine Tablets 250 mg (as terbinafine hydrochloride) Antifungal Agent Mylan Pharmaceuticals ULC 85 Advance Road Etobicoke, ON M8Z 2S6 Submission Control No.: 196573 Date of Revision: July 29, 2016 Page 2 of 43 TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ......................................................... 3 SUMMARY PRODUCT INFORMATION ................................................................................ 3 INDICATIONS AND CLINICAL USE ..................................................................................... 3 CONTRAINDICATIONS .......................................................................................................... 3 WARNINGS AND PRECAUTIONS ......................................................................................... 4 ADVERSE REACTIONS ........................................................................................................... 7 DRUG INTERACTIONS ......................................................................................................... 10 DOSAGE AND ADMINISTRATION ..................................................................................... 13 OVERDOSAGE ....................................................................................................................... 14 ACTION AND CLINICAL PHARMACOLOGY .................................................................... 14 STORAGE AND STABILITY ................................................................................................. 16 DOSAGE FORMS, COMPOSITION AND PACKAGING ..................................................... 16 PART II: SCIENTIFIC INFORMATION ............................................................................... 17 PHARMACEUTICAL INFORMATION ................................................................................. 17 CLINICAL TRIALS ................................................................................................................. 18 DE Leia o documento completo